Executive Summary

The global market opportunity is substantial, with over 1.6 million PCI and CABG procedures performed annually linked to bifurcation disease. This represents an addressable market exceeding $8 billion.

ABS was founded by cardiologist Dr. Mehran Khorsandi and veteran medical devices engineer Henry Bourang. Together, they have tackled one of the most challenging problems in interventional cardiology: the treatment of coronary bifurcation lesions. This issue has remained unsolved since the first human implant of a coronary stent in 1986.

Coronary bifurcation lesions present a significant challenge in interventional cardiology. These lesions occur in about 20% of Coronary Artery Bypass Grafting (CABG) procedures and 20% of Percutaneous Coronary Intervention (PCI) procedures. Patients facing these lesions currently have limited options:

1. Complex stenting procedures with suboptimal and unpredictable outcomes.
2. Open-heart CABG surgery, which carries higher risks and greater costs.

ABS is dedicated to addressing this critical gap in treatment with an innovative solution that simplifies the process and improves patient outcomes.

Unlike past attempts by other companies to solve this problem, the ABS System focuses on the delivery platform, not only the stent. It is a groundbreaking proprietary stent delivery platform designed to efficiently and predictably treat coronary bifurcation lesions. The ABS System is fully developed.  First-in-human trials have been completed across three international medical centers, with a 100% success rate.

ABS enables provisional stenting without rewiring or stent deformation.

This innovative platform simplifies bifurcation stenting and offers predictable results, transforming how these challenging lesions are treated.

• Simplified Approach: Designed to address the growing clinical challenge of bifurcation lesions (~20% of coronary PCIs and ~20% of CABGs).
• Efficient Design: The 6F bifurcation platform allows for automatic orientation and alignment, enabling full lesion coverage and side-branch access in just 10–15 minutes.
• Extensive Testing: In first-in-human trials (n=10), ABS achieved 100% procedural success with no MACE events at 12 months
• Regulatory Progress: Granted the FDA Breakthrough Device Designation, accelerating our regulatory and reimbursement pathway
• Patents: Secured 95+ issued and 35+ pending patents worldwide, with full freedom-to-operate opinions
• Significant Investment: Raised $58+ million to date, including investment from Johnson & Johnson and Cedars-Sinai
• Manufacturing Capabilities: ABS operates a scalable in-house manufacturing facility in the San Francisco Bay Area
• Clinical Validation and Safety: Peer-reviewed publications confirm the ABS platform’s safety, efficacy, and reproducibility

With a $8 billion+ addressable market, ABS has the backing of leading institutional investors, a prestigious Board of Directors, and global Key Opinion Leader (KOL) support from top cardiologists. Our fully developed product offers multiple exit pathways with flexible timing alternatives.

At ABS, we are committed to improving patient outcomes and advancing the treatment of coronary bifurcation lesions. With a cutting-edge system, global support, and a clear path forward, ABS is poised to redefine interventional cardiology.